🇺🇸 FDA
Patent

US 10919932

Bi-terminal pegylated integrin-binding peptides and methods of use thereof

granted A61KA61K31/337A61K38/00

Quick answer

US patent 10919932 (Bi-terminal pegylated integrin-binding peptides and methods of use thereof) held by The Regents of the University of California expires Mon Feb 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Feb 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
46
CPC classes
A61K, A61K31/337, A61K38/00, A61K47/60, A61K47/64